|
G |
Hmbs |
hydroxymethylbilane synthase |
decreases activity |
ISO |
Calcium ion decreases activity of purified Hmbs protein |
RGD |
PMID:6732900 |
RGD:25394584 |
NCBI chr 9:44,247,645...44,255,525
Ensembl chr 9:44,247,636...44,255,525
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of ABCA1 mRNA Atorvastatin results in decreased expression of ABCA1 mRNA; Atorvastatin results in decreased expression of ABCA1 protein [Rosiglitazone co-treated with Atorvastatin] results in increased expression of ABCA1 protein |
CTD |
PMID:15183127 PMID:16386711 PMID:25278499 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions decreases activity |
ISO |
Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atorvastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:15901796 PMID:23956101 PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions decreases expression decreases activity increases transport |
ISO |
ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Atorvastatin]; Atorvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Atorvastatin results in decreased expression of ABCB1A mRNA Atorvastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Atorvastatin; ABCB1 protein results in increased transport of Atorvastatin analog |
CTD |
PMID:10751037 PMID:15616150 PMID:19802823 PMID:24502637 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
increases expression |
EXP |
Atorvastatin results in increased expression of ABCB4 mRNA; Atorvastatin results in increased expression of ABCB4 protein |
CTD |
PMID:15986414 PMID:25278499 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
decreases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Atorvastatin analog; Atorvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Atorvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Atorvastatin results in increased expression of ABCC2 mRNA |
CTD |
PMID:15616150 PMID:23562342 PMID:25278499 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression |
EXP |
Atorvastatin results in increased expression of ABCC3 mRNA; Atorvastatin results in increased expression of ABCC3 protein |
CTD |
PMID:15986414 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases expression |
EXP |
Atorvastatin results in increased expression of ABCG2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Atorvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Atorvastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acacb |
acetyl-Coenzyme A carboxylase beta |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of ACACB mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ACACB mRNA] |
CTD |
PMID:12056585 |
|
NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ACE mRNA |
CTD |
PMID:23390189 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ACE2 mRNA |
CTD |
PMID:23390189 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ACTA2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of ADAM12 protein |
CTD |
PMID:18360054 |
|
NCBI chr 7:133,484,928...133,826,859
Ensembl chr 7:133,484,928...133,833,875
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of ADAM17 protein |
CTD |
PMID:18360054 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 protein] |
CTD |
PMID:37023836 |
|
NCBI chr17:57,665,650...57,790,527
Ensembl chr17:57,665,691...57,790,527
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression increases expression |
ISO |
Atorvastatin results in decreased expression of ADIPOQ protein Atorvastatin results in increased expression of ADIPOQ protein |
CTD |
PMID:19651449 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased abundance of Malondialdehyde]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Akr7a5 |
aldo-keto reductase family 7, member A5 |
increases expression |
ISO |
Atorvastatin results in increased expression of AKR7A2 mRNA; Atorvastatin results in increased expression of AKR7A2 protein |
CTD |
PMID:38484826 |
|
NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of AKT1 protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of AKT1 protein]; coenzyme Q10 inhibits the reaction [Atorvastatin results in decreased phosphorylation of AKT1 protein] Atorvastatin results in increased phosphorylation of AKT1 protein [Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of AKT1 protein; Atorvastatin results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:18172863 PMID:19526287 PMID:20305681 PMID:27345130 PMID:27815113 PMID:29630879 PMID:32259528 More...
|
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ANGPT2 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr 8:18,740,279...18,791,578
Ensembl chr 8:18,740,279...18,791,578
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion decreases expression |
ISO |
Atorvastatin results in decreased expression of and results in decreased secretion of APOB protein Atorvastatin inhibits the reaction [Fructose results in increased expression of APOB protein] Atorvastatin results in decreased secretion of APOB protein Atorvastatin results in decreased expression of APOB protein |
CTD |
PMID:9512650 PMID:10357840 PMID:11728391 PMID:12065722 PMID:12172771 PMID:12612140 PMID:12633795 PMID:18702965 More...
|
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoe |
apolipoprotein E |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of APOE mRNA; Atorvastatin results in decreased expression of APOE protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein |
CTD |
PMID:16386711 PMID:19603250 PMID:32976958 PMID:37121058 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein]; Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ATF6 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases response to substance |
EXP |
ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of BAK1 protein |
CTD |
PMID:19935899 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of BAX protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein] |
CTD |
PMID:19935899 PMID:37121058 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of BCL2 mRNA; Atorvastatin results in decreased expression of BCL2 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of BCL2 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:16470222 PMID:31423616 PMID:32259528 PMID:37121058 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Becn1 |
beclin 1, autophagy related |
increases expression |
EXP |
Atorvastatin results in increased expression of BECN1 protein |
CTD |
PMID:20876807 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Atorvastatin results in increased expression of BGLAP mRNA |
CTD |
PMID:17252541 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
Atorvastatin results in decreased expression of and results in increased cleavage of BID protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein]; U 0126 inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein] |
CTD |
PMID:18339080 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of BIRC5 mRNA; Atorvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17372815 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression increases secretion |
ISO |
Atorvastatin results in increased expression of BMP2 mRNA Atorvastatin results in increased secretion of BMP2 protein |
CTD |
PMID:16470222 PMID:17252541 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
C3 |
complement component 3 |
multiple interactions |
ISO |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of C3 protein modified form] |
CTD |
PMID:20946910 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CASP1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
increases activity decreases activity multiple interactions increases cleavage |
ISO EXP |
Atorvastatin results in increased activity of CASP3 protein Atorvastatin results in decreased activity of CASP3 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] Atorvastatin results in increased cleavage of CASP3 protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of and results in increased activity of CASP3 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:18339080 PMID:19429019 PMID:20305681 PMID:20876807 PMID:20946910 PMID:30511338 PMID:31423616 PMID:37121058 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP8 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP8 protein]; [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of CASP8 protein] Atorvastatin results in increased activity of CASP8 protein |
CTD |
PMID:15705602 PMID:18172863 PMID:20946910 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP9 protein Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:15705602 PMID:16470222 PMID:18172863 PMID:18339080 PMID:29630879 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] Atorvastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 PMID:25218292 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin results in decreased expression of and results in decreased secretion of CCL2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of CCL2 mRNA] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CCL2 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CCL2 protein] |
CTD |
PMID:12117737 PMID:25058445 PMID:34939712 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cd14 |
CD14 antigen |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD14 protein |
CTD |
PMID:18333374 |
|
NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 mRNA]; Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CD36 protein] |
CTD |
PMID:15183127 PMID:16386711 PMID:32259528 |
|
NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
|
|
G |
Cd40 |
CD40 antigen |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40 protein |
CTD |
PMID:16387846 |
|
NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40LG protein |
CTD |
PMID:16368305 PMID:19171469 |
|
NCBI chr X:56,257,448...56,269,402
Ensembl chr X:56,257,503...56,269,402
|
|
G |
Cd83 |
CD83 antigen |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608
|
|
G |
Cd86 |
CD86 antigen |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of CDH1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1A protein; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] Atorvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:18172863 PMID:20876807 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1B protein Atorvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:16470222 PMID:18172863 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19800637 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Clcn1 |
chloride channel, voltage-sensitive 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CLCN1 protein |
CTD |
PMID:27377005 |
|
NCBI chr 6:42,263,552...42,292,693
Ensembl chr 6:42,263,619...42,292,690
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:17252541 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of CPT1A mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased expression of CPT1A mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions decreases expression |
ISO |
[Atorvastatin co-treated with Amlodipine] results in decreased expression of CRP protein; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP mRNA]; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CRP protein] Atorvastatin results in decreased expression of CRP protein |
CTD |
PMID:16025360 PMID:16360360 PMID:17673219 PMID:18389332 PMID:21584495 PMID:25058445 More...
|
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cs |
citrate synthase |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of CS mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of CS mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 protein] |
CTD |
PMID:19482827 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CXCL10 |
CTD |
PMID:15831368 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases expression decreases secretion decreases expression |
ISO |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CXCL8 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CXCL8 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CXCL8 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CXCL8 protein]; Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; Atorvastatin results in decreased expression of and results in decreased secretion of CXCL8 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of CXCL8 mRNA] Atorvastatin results in increased expression of CXCL8 protein Atorvastatin results in decreased secretion of CXCL8 protein Atorvastatin results in decreased expression of CXCL8 mRNA; Atorvastatin results in decreased expression of CXCL8 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:16410222 PMID:19171469 PMID:19482827 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CYBA mRNA] |
CTD |
PMID:25218292 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CYCS protein] Atorvastatin affects the localization of CYCS protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the localization of CYCS protein] |
CTD |
PMID:31423616 PMID:32259528 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
ISO |
Atorvastatin affects the expression of CYP11A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP17A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP19A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO EXP |
Atorvastatin results in decreased expression of CYP27A1 mRNA; Atorvastatin results in decreased expression of CYP27A1 protein Atorvastatin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:16386711 PMID:25278499 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
increases expression |
ISO EXP |
Atorvastatin results in increased expression of CYP2B6 mRNA Atorvastatin results in increased expression of CYP2B10 mRNA; Atorvastatin results in increased expression of CYP2B10 protein |
CTD |
PMID:15802384 PMID:15986414 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP39A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr17:43,978,263...44,062,322
Ensembl chr17:43,978,316...44,062,322
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP3A11 mRNA; Atorvastatin results in increased expression of CYP3A11 protein |
CTD |
PMID:15986414 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of CYP7A1 mRNA Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:25278499 PMID:32048413 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502
|
|
G |
Dcx |
doublecortin |
increases expression |
ISO |
Atorvastatin results in increased expression of DCX protein |
CTD |
PMID:15255259 |
|
NCBI chr X:142,638,838...142,716,392
Ensembl chr X:142,638,838...142,716,307
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression multiple interactions increases activity |
ISO |
Atorvastatin results in increased expression of DGAT1 mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of DGAT1 protein] |
CTD |
PMID:12056585 |
|
NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
affects response to substance |
ISO |
DSCC1 protein affects the susceptibility to Atorvastatin |
CTD |
PMID:35926565 |
|
NCBI chr15:54,939,497...54,953,887
Ensembl chr15:54,939,495...54,953,887
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of EDN1 protein |
CTD |
PMID:16360360 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions decreases expression |
ISO |
Atorvastatin promotes the reaction [Losartan results in decreased expression of EDNRA mRNA]; Losartan promotes the reaction [Atorvastatin results in decreased expression of EDNRA mRNA] |
CTD |
PMID:23091284 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:18360054 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases response to substance |
ISO |
EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
multiple interactions increases phosphorylation |
ISO |
4-phenylbutyric acid inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:20876807 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
multiple interactions |
ISO |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein] |
CTD |
PMID:20946910 |
|
NCBI chr 4:131,650,724...131,802,824
Ensembl chr 4:131,650,724...131,802,632
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F2 protein |
CTD |
PMID:16907931 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
F5 |
coagulation factor V |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F5 protein |
CTD |
PMID:16907931 |
|
NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of FADD protein] |
CTD |
PMID:20946910 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Fas |
Fas cell surface death receptor |
affects expression |
ISO |
Atorvastatin affects the expression of FAS mRNA; Atorvastatin affects the expression of FAS protein |
CTD |
PMID:17372815 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Acetylcysteine] inhibits the reaction [sodium arsenite results in increased expression of FASLG protein] Atorvastatin results in increased expression of FASLG protein modified form Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form] |
CTD |
PMID:15063428 PMID:20946910 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of FASN mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of FASN mRNA] |
CTD |
PMID:11728391 PMID:12056585 PMID:32259528 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression |
ISO |
Atorvastatin results in increased expression of FBXO32 mRNA |
CTD |
PMID:27377005 |
|
NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of FGF15 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
EXP |
Atorvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein] |
CTD |
PMID:32976958 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gck |
glucokinase |
decreases expression multiple interactions |
ISO |
Atorvastatin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
Atorvastatin promotes the reaction [dapagliflozin inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of GJA1 protein]] |
CTD |
PMID:34939712 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gng3 |
guanine nucleotide binding protein (G protein), gamma 3 |
multiple interactions affects localization |
ISO |
[Isoproterenol co-treated with Atorvastatin] affects the localization of GNG3 protein Atorvastatin affects the localization of GNG3 protein |
CTD |
PMID:19136528 |
|
NCBI chr19:8,814,293...8,816,610
Ensembl chr19:8,814,297...8,816,558
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1, soluble |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GOT1 protein] |
CTD |
PMID:30657622 |
|
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of GPAM mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr19:55,056,067...55,115,666
Ensembl chr19:55,055,700...55,115,670
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP ISO |
[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein] [Atorvastatin co-treated with triptolide] results in increased expression of GPT protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GPT protein] |
CTD |
PMID:29679711 PMID:30657622 PMID:32259528 PMID:32976958 PMID:33600922 PMID:36006763 PMID:37023836 More...
|
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein] |
CTD |
PMID:32976958 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
decreases expression |
EXP |
Atorvastatin results in decreased expression of HBEGF protein |
CTD |
PMID:18360054 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions affects binding increases expression increases activity |
ISO |
Atorvastatin results in increased expression of and results in increased activity of HMGCR protein Atorvastatin binds to HMGCR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Atorvastatin results in increased expression of and results in increased activity of HMGCR protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of HMGCR mRNA] |
CTD |
PMID:9512650 PMID:10357840 PMID:12056585 PMID:12065722 PMID:12612140 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of HMOX1 mRNA Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein] |
CTD |
PMID:16410222 PMID:32259528 PMID:32976958 PMID:38484826 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnf4a |
hepatic nuclear factor 4, alpha |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830
|
|
G |
Htr7 |
5-hydroxytryptamine (serotonin) receptor 7 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of HTR7 mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of HTR7 mRNA]] |
CTD |
PMID:32329363 |
|
NCBI chr19:35,935,815...36,035,533
Ensembl chr19:35,936,134...36,034,907
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1] Atorvastatin results in increased expression of ICAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of ICAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein] |
CTD |
PMID:12615677 PMID:17589825 PMID:19171469 PMID:25058445 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:19800637 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il12a |
interleukin 12a |
decreases expression |
ISO |
Atorvastatin results in decreased expression of IL12A mRNA |
CTD |
PMID:12492458 |
|
NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:37023836 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:17589825 PMID:19482827 PMID:25058445 PMID:32048413 PMID:34939712 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2ra |
interleukin 2 receptor, alpha chain |
affects expression |
ISO |
Atorvastatin affects the expression of IL2RA protein |
CTD |
PMID:16387846 |
|
NCBI chr 2:11,647,603...11,698,005
Ensembl chr 2:11,647,618...11,698,004
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Atorvastatin results in decreased expression of and results in decreased secretion of IL6 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of IL6 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 protein] Atorvastatin results in decreased expression of IL6 mRNA; Atorvastatin results in decreased expression of IL6 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of IL6 mRNA]]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of IL6 mRNA]]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Atorvastatin results in decreased secretion of IL6 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:17521631 PMID:19171469 PMID:19482827 PMID:19800637 PMID:25058445 PMID:25834641 PMID:32048413 PMID:32329363 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of INS1 protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of INS1 protein] |
CTD |
PMID:19800637 PMID:34939712 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
increases expression |
ISO |
Atorvastatin results in increased expression of INS protein |
CTD |
PMID:19651449 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of IRAK1 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
|
|
G |
Itga2 |
integrin alpha 2 |
multiple interactions |
ISO |
Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]] |
CTD |
PMID:12500026 |
|
NCBI chr13:114,969,617...115,068,588
Ensembl chr13:114,969,617...115,068,636
|
|
G |
Itgal |
integrin alpha L |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgam |
integrin alpha M |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAM protein |
CTD |
PMID:18333374 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgax |
integrin alpha X |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAX protein |
CTD |
PMID:18333374 |
|
NCBI chr 7:127,728,697...127,749,829
Ensembl chr 7:127,728,719...127,749,829
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of ITGB1 mRNA Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ITGB1 mRNA] |
CTD |
PMID:12500026 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2] |
CTD |
PMID:12615677 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of JUN protein; Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein; Celecoxib promotes the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein] |
CTD |
PMID:18172863 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity multiple interactions |
ISO |
Atorvastatin results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of KHK protein] |
CTD |
PMID:21122807 |
|
NCBI chr 5:31,078,780...31,088,592
Ensembl chr 5:31,078,775...31,088,592
|
|
G |
Kif6 |
kinesin family member 6 |
increases response to substance |
ISO |
KIF6 polymorphism results in increased susceptibility to Atorvastatin |
CTD |
PMID:21943003 |
|
NCBI chr17:49,922,121...50,216,875
Ensembl chr17:49,922,164...50,216,875
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
multiple interactions affects localization |
ISO |
[Ivermectin co-treated with Atorvastatin] affects the localization of KPNA2 protein Atorvastatin affects the localization of KPNA2 protein |
CTD |
PMID:34696514 |
|
NCBI chr11:106,879,455...106,890,351
Ensembl chr11:106,879,455...106,890,367
|
|
G |
Kpna7 |
karyopherin subunit alpha 7 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr 5:144,920,537...144,946,446
Ensembl chr 5:144,920,329...145,020,840
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] |
CTD |
PMID:30273964 |
|
NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein] |
CTD |
PMID:29679711 PMID:32259528 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity multiple interactions increases expression |
ISO |
Atorvastatin results in increased activity of LDLR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of LDLR mRNA] Atorvastatin results in increased expression of LDLR mRNA |
CTD |
PMID:10357840 PMID:11728391 PMID:12612140 PMID:24502637 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Atorvastatin affects the reaction [Fructose results in increased expression of LEP protein] |
CTD |
PMID:21122807 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] |
CTD |
PMID:30273964 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:34939712 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
EXP ISO |
Atorvastatin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:17589825 PMID:19767766 PMID:20018284 PMID:20305681 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mb |
myoglobin |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of MB protein [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:27815113 PMID:29679711 |
|
NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MCL1 protein |
CTD |
PMID:16470222 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of MDM2 protein |
CTD |
PMID:29630879 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
increases expression |
ISO |
Atorvastatin results in increased expression of MEF2D mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 3:88,049,248...88,079,398
Ensembl chr 3:88,049,679...88,079,393
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of MFN2 protein] |
CTD |
PMID:24721408 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 1:20,752,993...20,753,111
Ensembl chr 1:20,752,993...20,753,111
|
|
G |
Mir145a |
microRNA 145a |
increases expression |
ISO |
Atorvastatin results in increased expression of MIR145 mRNA |
CTD |
PMID:29630879 |
|
NCBI chr18:61,780,896...61,780,965
Ensembl chr18:61,780,896...61,780,965
|
|
G |
Mir146 |
microRNA 146 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146A; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146A |
CTD |
PMID:20524934 |
|
NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288
|
|
G |
Mir146b |
microRNA 146b |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146B; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146B |
CTD |
PMID:20524934 |
|
NCBI chr19:46,331,201...46,331,309
Ensembl chr19:46,331,201...46,331,309
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 1:20,749,234...20,749,306
Ensembl chr 1:20,749,234...20,749,306
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:19,012,533...19,012,627
Ensembl chr X:19,012,533...19,012,627
|
|
G |
Mir222 |
microRNA 222 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR222 |
CTD |
PMID:25517390 |
|
NCBI chr X:19,013,132...19,013,210
Ensembl chr X:19,013,132...19,013,210
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose affects the localization of and results in increased activity of MLXIPL protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of MLXIPL protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr 5:135,118,744...135,168,622
Ensembl chr 5:135,118,744...135,167,236
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression increases activity |
EXP ISO |
Atorvastatin results in decreased expression of MMP2 protein Atorvastatin results in increased activity of MMP2 protein |
CTD |
PMID:18360054 PMID:23831763 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
ISO |
Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Sildenafil Citrate promotes the reaction [Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]] Atorvastatin results in increased activity of MMP9 protein |
CTD |
PMID:15728660 PMID:23831763 PMID:26614570 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Paraquat results in increased activity of MPO protein] |
CTD |
PMID:27883937 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of MSR1 mRNA |
CTD |
PMID:15183127 |
|
NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714
|
|
G |
Mstn |
myostatin |
increases expression |
EXP |
Atorvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
affects expression multiple interactions |
ISO |
Atorvastatin affects the expression of COX1 mRNA Quercetin inhibits the reaction [Atorvastatin affects the expression of COX1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
Mt2 |
metallothionein 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of MT2A mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of and results in increased phosphorylation of MTOR protein] |
CTD |
PMID:34939712 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions decreases expression |
ISO |
Atorvastatin results in increased expression of MTTP mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of MTTP mRNA] Atorvastatin results in decreased expression of MTTP mRNA |
CTD |
PMID:10357840 PMID:12056585 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MYC mRNA |
CTD |
PMID:29630879 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 protein] |
CTD |
PMID:38213245 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Myh2 |
myosin, heavy polypeptide 2, skeletal muscle, adult |
affects expression multiple interactions |
EXP |
Atorvastatin affects the expression of MYH2 protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein |
CTD |
PMID:30511338 |
|
NCBI chr11:67,061,853...67,088,343
Ensembl chr11:67,061,853...67,088,343
|
|
G |
Nfe2l1 |
nuclear factor, erythroid derived 2,-like 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of NFE2L1 mRNA |
CTD |
PMID:30511338 |
|
NCBI chr11:96,708,239...96,720,810
Ensembl chr11:96,708,240...96,720,794
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions increases expression decreases expression |
EXP ISO |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein] Atorvastatin results in increased expression of NFE2L2 mRNA Atorvastatin results in decreased expression of NFE2L2 protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of NFE2L2 protein]; Atorvastatin results in increased expression of and affects the localization of and results in increased activity of NFE2L2 protein [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein] |
CTD |
PMID:30511338 PMID:31423616 PMID:32259528 PMID:32976958 PMID:38484826 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO EXP |
[Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34696514 PMID:37023836 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of NLRP3 protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NLRP3 mRNA] |
CTD |
PMID:34939712 PMID:37023836 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression |
ISO |
Atorvastatin results in increased expression of NNMT protein |
CTD |
PMID:33073877 |
|
NCBI chr 9:48,448,905...48,518,958
Ensembl chr 9:48,503,177...48,516,453
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions decreases expression |
ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein] Atorvastatin results in decreased expression of NOS2 mRNA; Atorvastatin results in decreased expression of NOS2 protein |
CTD |
PMID:15166393 PMID:25058445 PMID:25218292 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions increases expression affects response to substance |
ISO EXP |
Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]; Melatonin promotes the reaction [Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]] Atorvastatin results in increased expression of NOS3 mRNA; Atorvastatin results in increased expression of NOS3 protein [Dexamethasone co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; [Losartan co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of and results in decreased phosphorylation of NOS3 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS3 protein]; Atorvastatin inhibits the reaction [Streptozocin results in decreased expression of NOS3 protein] Atorvastatin inhibits the reaction [Homocysteine results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of NOS3 protein] NOS3 promoter SNP affects the susceptibility to Atorvastatin |
CTD |
PMID:12490971 PMID:15166393 PMID:16410222 PMID:16962929 PMID:17042910 PMID:17589825 PMID:20305681 PMID:21585521 PMID:23091284 PMID:25058445 PMID:25218292 PMID:25517390 More...
|
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr X:132,987,170...133,038,455
Ensembl chr X:132,987,170...133,122,705
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOX4 mRNA] Atorvastatin inhibits the reaction [Homocysteine results in increased expression of NOX4 mRNA] |
CTD |
PMID:20018284 PMID:25218292 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA] |
CTD |
PMID:19136528 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nppb |
natriuretic peptide type B |
decreases expression |
EXP |
Atorvastatin results in decreased expression of NPPB protein |
CTD |
PMID:18360054 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases expression |
ISO EXP |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] Atorvastatin promotes the reaction [Dietary Fats results in increased expression of NR1I2 protein] Atorvastatin binds to and results in increased activity of NR1I2 protein Atorvastatin results in increased expression of NR1I2 protein |
CTD |
PMID:15986414 PMID:24204015 PMID:26616219 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
Atorvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions affects expression increases expression |
ISO |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of NRF1 mRNA]; Quercetin inhibits the reaction [Atorvastatin affects the expression of NRF1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr 6:30,047,984...30,153,462
Ensembl chr 6:30,047,987...30,153,457
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of PARP1 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:20876807 PMID:31423616 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1, choline, alpha isoform |
increases activity |
ISO |
Atorvastatin results in increased activity of PCYT1A protein |
CTD |
PMID:12056585 |
|
NCBI chr16:32,249,739...32,293,883
Ensembl chr16:32,249,739...32,293,888
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] |
CTD |
PMID:22343369 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of and results in decreased expression of PDPK1 protein |
CTD |
PMID:18172863 |
|
NCBI chr17:24,292,654...24,370,957
Ensembl chr17:24,292,654...24,369,898
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PIK3CA mRNA |
CTD |
PMID:29630879 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pklr |
pyruvate kinase liver and red blood cell |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of PKLR mRNA] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091
|
|
G |
Pkm |
pyruvate kinase, muscle |
increases expression |
ISO |
Atorvastatin results in increased expression of PKM mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PLAU protein |
CTD |
PMID:16410222 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PLIN2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 4:86,545,147...86,588,518
Ensembl chr 4:86,566,623...86,588,297
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
increases expression |
ISO |
Atorvastatin results in increased expression of POMC protein |
CTD |
PMID:29574565 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity multiple interactions increases expression |
ISO |
Atorvastatin results in increased activity of PON1 protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] PON1 gene polymorphism affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL] Atorvastatin results in increased expression of PON1 mRNA |
CTD |
PMID:15324535 PMID:15690306 PMID:15969877 PMID:16238680 PMID:30273964 |
|
NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
ISO |
Atorvastatin results in increased activity of PON2 protein Atorvastatin results in increased expression of PON2 mRNA |
CTD |
PMID:14592851 |
|
NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of PPARA mRNA Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARA protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of PPARA protein] |
CTD |
PMID:12065722 PMID:18812576 PMID:21554872 PMID:32259528 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA] |
CTD |
PMID:36006763 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
decreases expression affects expression multiple interactions increases expression |
ISO EXP |
Atorvastatin results in decreased expression of PPARGC1A mRNA Atorvastatin affects the expression of PPARGC1A mRNA Atorvastatin results in decreased expression of PPARGC1A protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA Atorvastatin results in increased expression of PPARGC1A mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARGC1A protein]; Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of PPARGC1A mRNA]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]] |
CTD |
PMID:21775390 PMID:22343369 PMID:30511338 PMID:32259528 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
affects expression affects response to substance decreases expression multiple interactions |
ISO EXP |
Atorvastatin affects the expression of PPARGC1B mRNA PPARGC1B protein affects the susceptibility to Atorvastatin Atorvastatin affects the expression of PPARGC1B protein Atorvastatin results in decreased expression of PPARGC1B mRNA [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1B mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein Quercetin inhibits the reaction [Atorvastatin affects the expression of PPARGC1B mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isoform |
increases expression |
ISO |
Atorvastatin results in increased expression of PPP3CA mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 3:136,375,778...136,643,488
Ensembl chr 3:136,375,885...136,643,488
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases activity |
ISO |
Atorvastatin results in increased activity of PRKAA1 protein |
CTD |
PMID:33073877 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkaca |
protein kinase, cAMP dependent, catalytic, alpha |
multiple interactions |
ISO |
Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein] |
CTD |
PMID:19053045 |
|
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of and results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:32259528 |
|
NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754
|
|
G |
Prkcq |
protein kinase C, theta |
increases expression |
ISO |
Atorvastatin results in increased expression of PRKCQ mRNA; Atorvastatin results in increased expression of PRKCQ protein |
CTD |
PMID:27377005 |
|
NCBI chr 2:11,176,922...11,306,033
Ensembl chr 2:11,176,919...11,306,033
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PRKCZ protein] |
CTD |
PMID:32259528 |
|
NCBI chr 4:155,344,579...155,445,856
Ensembl chr 4:155,344,586...155,445,818
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Atorvastatin results in increased expression of PTEN protein |
CTD |
PMID:15837263 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Pioglitazone] results in increased expression of PTGS2 protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PTGS2 protein] Atorvastatin results in increased expression of PTGS2 protein |
CTD |
PMID:16908763 PMID:34939712 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO EXP |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RAC1 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of and results in increased localization of RAC1 protein] |
CTD |
PMID:17279352 PMID:17589825 PMID:34696514 |
|
NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased expression of RB1 protein modified form; [Atorvastatin co-treated with Celecoxib] results in increased expression of RB1 protein |
CTD |
PMID:18172863 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [Nitroglycerin results in increased localization of RELA protein] Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein] |
CTD |
PMID:19733216 PMID:34939712 PMID:37121058 PMID:38213245 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rhoa |
ras homolog family member A |
increases expression decreases activity multiple interactions decreases localization |
ISO |
Atorvastatin results in increased expression of RHOA protein Atorvastatin results in decreased activity of RHOA protein Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RHOA protein] [Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA; Atorvastatin results in increased localization of and results in decreased prenylation of RHOA protein; Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOA protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:17589825 PMID:18172863 PMID:34696514 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rhob |
ras homolog family member B |
increases localization increases expression multiple interactions |
ISO |
Atorvastatin results in increased localization of RHOB protein Atorvastatin results in increased expression of RHOB protein [Atorvastatin co-treated with Celecoxib] results in increased localization of RHOB protein; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOB protein] |
CTD |
PMID:18172863 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rhoc |
ras homolog family member C |
decreases localization multiple interactions increases expression |
ISO |
Atorvastatin results in decreased localization of RHOC protein Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOC protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOC protein] |
CTD |
PMID:18172863 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of SCARB1 protein |
CTD |
PMID:15183127 |
|
NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SCD1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sele |
selectin, endothelial cell |
increases expression |
ISO |
Atorvastatin results in increased expression of SELE protein |
CTD |
PMID:19171469 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr 2:162,829,249...162,856,059
Ensembl chr 2:162,829,250...162,856,047
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases phosphorylation |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SIRT1 protein] Atorvastatin results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:33073877 PMID:34939712 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of SLC10A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc10a2 |
solute carrier family 10, member 2 |
increases expression |
EXP |
Atorvastatin results in increased expression of SLC10A2 mRNA; Atorvastatin results in increased expression of SLC10A2 protein |
CTD |
PMID:15986414 |
|
NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351
|
|
G |
Slc1a2 |
solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein] |
CTD |
PMID:20816828 |
|
NCBI chr 2:102,488,584...102,621,129
Ensembl chr 2:102,489,004...102,621,129
|
|
G |
Slc1a3 |
solute carrier family 1 (glial high affinity glutamate transporter), member 3 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr15:8,663,608...8,742,648
Ensembl chr15:8,663,608...8,740,248
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
multiple interactions increases expression |
ISO EXP |
Atorvastatin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Atorvastatin results in increased expression of SLC22A1 mRNA |
CTD |
PMID:21641380 PMID:25278499 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Slc22a3 |
solute carrier family 22 (organic cation transporter), member 3 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr17:12,638,859...12,726,591
Ensembl chr17:12,637,847...12,726,591
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:21641380 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr17:45,896,126...45,910,544
Ensembl chr17:45,896,126...45,910,532
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
decreases expression multiple interactions |
ISO |
Atorvastatin results in decreased expression of SLC2A2 protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] |
CTD |
PMID:26616219 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 protein] |
CTD |
PMID:19800637 PMID:25834641 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc4a1 |
solute carrier family 4 (anion exchanger), member 1 |
multiple interactions |
ISO |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite affects the localization of SLC4A1 protein] |
CTD |
PMID:20946910 |
|
NCBI chr11:102,239,646...102,256,107
Ensembl chr11:102,239,650...102,257,029
|
|
G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 protein] |
CTD |
PMID:17575010 |
|
NCBI chr11:76,889,423...76,923,169
Ensembl chr11:76,889,429...76,923,166
|
|
G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of SLCO1A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:141,853,007...141,892,688
Ensembl chr 6:141,853,008...141,892,688
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression decreases expression |
EXP ISO |
Atorvastatin results in increased expression of SLCO1A4 mRNA; Atorvastatin results in increased expression of SLCO1A4 protein Atorvastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:15986414 PMID:24909372 PMID:25278499 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
increases expression increases uptake multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of SLCO1B2 mRNA SLCO1B3 protein results in increased uptake of Atorvastatin glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 PMID:25278499 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions increases uptake |
ISO |
glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions affects expression decreases expression increases expression |
ISO EXP |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of SOD2 mRNA]; Quercetin affects the reaction [Atorvastatin affects the expression of SOD2 mRNA] Atorvastatin affects the expression of SOD2 protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the expression of SOD2 protein] [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein Atorvastatin results in decreased expression of SOD2 protein |
CTD |
PMID:21775390 PMID:30511338 PMID:31423616 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sod3 |
superoxide dismutase 3, extracellular |
increases expression |
ISO |
Atorvastatin results in increased expression of SOD3 protein |
CTD |
PMID:19451411 |
|
NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of SQSTM1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; Atorvastatin inhibits the reaction [Fructose results in increased activity of SREBF1 protein] |
CTD |
PMID:19053045 PMID:32259528 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions increases expression increases localization |
ISO |
Atorvastatin results in increased activity of and results in increased localization of SREBF2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of SREBF2 mRNA] Atorvastatin results in increased localization of SREBF2 protein |
CTD |
PMID:11728391 PMID:12056585 PMID:12065722 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression |
ISO |
Atorvastatin affects the expression of STAR mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Syp |
synaptophysin |
increases expression |
ISO |
Atorvastatin results in increased expression of SYP protein |
CTD |
PMID:15255259 |
|
NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of TFAM mRNA Atorvastatin results in decreased expression of TFAM protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of TFAM mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110
|
|
G |
Tfrc |
transferrin receptor |
affects expression multiple interactions |
ISO EXP |
Atorvastatin affects the expression of TFRC protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein] |
CTD |
PMID:16387846 PMID:32976958 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24161914 PMID:32329363 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of TLR2 protein |
CTD |
PMID:16387846 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions decreases expression increases expression |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 protein; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 protein]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 protein] Atorvastatin results in decreased expression of TLR4 mRNA; Atorvastatin results in decreased expression of TLR4 protein Atorvastatin results in increased expression of TLR4 protein |
CTD |
PMID:16387846 PMID:20524934 PMID:27883937 PMID:38213245 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form]; Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of TNF mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of TNF mRNA]]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Atorvastatin inhibits the reaction [TNF protein results in increased oxidation of Glucose]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] Atorvastatin results in decreased expression of TNF mRNA Atorvastatin results in decreased secretion of TNF protein Atorvastatin results in decreased expression of TNF protein |
CTD |
PMID:12117737 PMID:12615677 PMID:15063428 PMID:16387846 PMID:17521631 PMID:17589825 PMID:19171469 PMID:19482827 PMID:19800637 PMID:22343369 PMID:29630879 PMID:32329363 PMID:34939712 PMID:36006763 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
decreases expression |
ISO |
Atorvastatin results in decreased expression of TNFRSF1A protein |
CTD |
PMID:16360360 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
increases response to substance |
ISO |
TNFSF10 protein results in increased susceptibility to Atorvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of TOMM20 protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein |
CTD |
PMID:30511338 |
|
NCBI chr 8:127,657,414...127,672,671
Ensembl chr 8:127,657,417...127,672,594
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TRAF6 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TRAF6 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of TP53 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] |
CTD |
PMID:29630879 PMID:37121058 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
ISO |
Atorvastatin results in increased expression of TUBB3 protein |
CTD |
PMID:15255259 |
|
NCBI chr 8:124,138,292...124,148,754
Ensembl chr 8:124,138,163...124,148,754
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression multiple interactions |
ISO |
Atorvastatin results in decreased expression of VCAM1 mRNA; Atorvastatin results in decreased expression of VCAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of VCAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 protein] |
CTD |
PMID:17589825 PMID:17673219 PMID:22245985 PMID:25058445 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vegfd |
vascular endothelial growth factor D |
affects expression |
ISO |
Atorvastatin affects the expression of VEGFD mRNA |
CTD |
PMID:16410222 |
|
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of VIM protein] |
CTD |
PMID:34939712 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Vwf |
Von Willebrand factor |
increases expression |
ISO |
Atorvastatin results in increased expression of VWF protein |
CTD |
PMID:19171469 |
|
NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of WT1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
EXP |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:119,842,821...119,852,660
Ensembl chr 9:119,842,821...119,852,664
|
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of BGLAP protein |
CTD |
PMID:2027271 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Capn1 |
calpain 1 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CAPN1 protein |
CTD |
PMID:24412303 |
|
NCBI chr19:6,038,573...6,065,855
Ensembl chr19:6,038,573...6,065,927
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CASP3 protein |
CTD |
PMID:24412303 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Calcium Carbonate analog results in increased expression of DDIT3 |
CTD |
PMID:24412303 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Pth |
parathyroid hormone |
affects expression decreases expression |
ISO |
Calcium Carbonate affects the expression of PTH protein Calcium Carbonate results in decreased expression of PTH protein |
CTD |
PMID:1752077 PMID:2027271 PMID:3826069 PMID:7891547 PMID:8481062 PMID:16006300 More...
|
|
NCBI chr 7:112,984,783...112,987,879
Ensembl chr 7:112,984,787...112,987,777
|
|
G |
Pthlh |
parathyroid hormone-like peptide |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of PTHLH protein |
CTD |
PMID:16006300 |
|
NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
Calcium Carbonate results in decreased expression of SPP1 protein |
CTD |
PMID:17977878 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
|
G |
Adam10 |
a disintegrin and metallopeptidase domain 10 |
increases expression |
ISO |
Calcium Chloride results in increased expression of ADAM10 mRNA; Calcium Chloride results in increased expression of ADAM10 protein |
CTD |
PMID:20621845 |
|
NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
increases expression |
ISO |
Calcium Chloride results in increased expression of ADAM17 mRNA; Calcium Chloride results in increased expression of ADAM17 protein |
CTD |
PMID:20621845 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
increases expression |
ISO |
Calcium Chloride results in increased expression of ALPL mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Apoc3 |
apolipoprotein C-III |
increases expression |
ISO |
Calcium Chloride results in increased expression of APOC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 9:46,144,348...46,146,934
Ensembl chr 9:46,144,231...46,146,934
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of ATP5PF protein |
CTD |
PMID:25824407 |
|
NCBI chr16:84,624,754...84,632,495
Ensembl chr16:84,624,754...84,632,513
|
|
G |
Bag4 |
BCL2-associated athanogene 4 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BAG4 protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:26,254,566...26,275,237
Ensembl chr 8:26,254,566...26,275,315
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Calcium Chloride results in increased expression of BGLAP mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bicd2 |
BICD cargo adaptor 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BICD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr13:49,495,025...49,540,502
Ensembl chr13:49,495,061...49,540,502
|
|
G |
Calm3 |
calmodulin 3 |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr 7:16,649,304...16,657,957
Ensembl chr 7:16,649,304...16,658,039
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP3 protein] |
CTD |
PMID:36731150 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO |
Calcium Chloride results in increased cleavage of CASP9 protein cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP9 protein] |
CTD |
PMID:36731150 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions increases activity |
ISO |
Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein] Calcium Chloride results in increased activity of CASR protein |
CTD |
PMID:16316325 PMID:17376781 |
|
NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases phosphorylation increases expression multiple interactions |
EXP |
Calcium Chloride results in increased phosphorylation of CCL2 protein Calcium Chloride results in increased expression of CCL2 mRNA; Calcium Chloride results in increased expression of CCL2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CCL2 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CCL2 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased phosphorylation of CCL2 protein] |
CTD |
PMID:21530968 PMID:22728078 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CCT6A protein |
CTD |
PMID:25824407 |
|
NCBI chr 5:129,864,420...129,875,284
Ensembl chr 5:129,864,062...129,875,212
|
|
G |
Cd68 |
CD68 antigen |
multiple interactions increases expression |
EXP |
resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CD68 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein] |
CTD |
PMID:12189186 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein] |
CTD |
PMID:12189186 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases activity |
ISO |
Calcium Chloride results in increased activity of CEBPA protein |
CTD |
PMID:17214633 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Clec3b |
C-type lectin domain family 3, member b |
increases expression |
ISO |
Calcium Chloride results in increased expression of CLEC3B protein |
CTD |
PMID:25824407 |
|
NCBI chr 9:122,980,011...122,986,497
Ensembl chr 9:122,980,011...122,986,497
|
|
G |
Clic3 |
chloride intracellular channel 3 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CLIC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:25,346,855...25,348,789
Ensembl chr 2:25,346,850...25,348,788
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of CMTM6 protein |
CTD |
PMID:25824407 |
|
NCBI chr 9:114,560,184...114,578,412
Ensembl chr 9:114,560,184...114,578,412
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL1A1 mRNA |
CTD |
PMID:25824407 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col8a1 |
collagen, type VIII, alpha 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL8A1 protein |
CTD |
PMID:25824407 |
|
NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
increases expression |
ISO |
Calcium Chloride results in increased expression of COPS3 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:59,708,621...59,739,080
Ensembl chr11:59,708,621...59,730,664
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Calcium Chloride results in increased expression of CST3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Cthrc1 |
collagen triple helix repeat containing 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CTHRC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr15:38,940,327...38,950,516
Ensembl chr15:38,940,327...38,950,516
|
|
G |
Ctsb |
cathepsin B |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of CTSB protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSB protein] |
CTD |
PMID:22728078 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsk |
cathepsin K |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of CTSK protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSK protein] |
CTD |
PMID:22728078 |
|
NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of DCN protein |
CTD |
PMID:25824407 |
|
NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005
|
|
G |
Ddx39b |
DEAD box helicase 39b |
increases expression |
ISO |
Calcium Chloride results in increased expression of DDX39B protein |
CTD |
PMID:25824407 |
|
NCBI chr17:35,460,722...35,472,683
Ensembl chr17:35,460,722...35,472,683
|
|
G |
Ehd2 |
EH-domain containing 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of EHD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:15,680,883...15,701,402
Ensembl chr 7:15,680,883...15,701,492
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676
|
|
G |
F11 |
coagulation factor XI |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr 8:45,693,696...45,715,092
Ensembl chr 8:45,694,211...45,715,068
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846
|
|
G |
F9 |
coagulation factor IX |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr X:59,044,675...59,076,120
Ensembl chr X:59,044,824...59,076,119
|
|
G |
Fyn |
Fyn proto-oncogene |
increases expression |
ISO |
Calcium Chloride results in increased expression of FYN protein |
CTD |
PMID:25824407 |
|
NCBI chr10:39,245,735...39,441,377
Ensembl chr10:39,244,851...39,441,377
|
|
G |
Git1 |
GIT ArfGAP 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of GIT1 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:77,384,114...77,398,600
Ensembl chr11:77,384,388...77,398,612
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
ISO |
[manganese chloride co-treated with Calcium Chloride] results in increased secretion of GNRH1 protein |
CTD |
PMID:18603625 |
|
NCBI chr14:67,982,717...67,986,889
Ensembl chr14:67,982,630...67,986,888
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
EXP |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions increases expression |
EXP |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
Calcium Chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21443188 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of HTRA1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of ICAM1 mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ift27 |
intraflagellar transport 27 |
increases expression |
ISO |
Calcium Chloride results in increased expression of IFT27 protein |
CTD |
PMID:25824407 |
|
NCBI chr15:78,043,660...78,058,281
Ensembl chr15:78,043,663...78,058,307
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
Calcium Chloride results in increased expression of IL1B protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of IL1B protein] |
CTD |
PMID:22728078 PMID:36731150 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr14:30,651,137...30,665,246
Ensembl chr14:30,651,137...30,665,246
|
|
G |
Itih2 |
inter-alpha trypsin inhibitor, heavy chain 2 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 2:10,099,408...10,135,492
Ensembl chr 2:10,099,404...10,136,207
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Calcium Chloride results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 7:43,447,001...43,453,250
Ensembl chr 7:43,447,001...43,453,250
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of LASP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590
|
|
G |
Lrrfip1 |
leucine rich repeat (in FLII) interacting protein 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of LRRFIP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:90,924,652...91,056,666
Ensembl chr 1:90,926,459...91,056,666
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Calcium Chloride results in increased phosphorylation of MAPK1 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21215118 PMID:33621091 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases expression multiple interactions increases phosphorylation |
ISO |
Calcium Chloride results in increased expression of MAPK3 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein] Calcium Chloride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21215118 PMID:25824407 PMID:33621091 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity multiple interactions |
ISO EXP |
Calcium Chloride results in increased expression of MMP2 mRNA; Calcium Chloride results in increased expression of MMP2 protein Calcium Chloride results in increased activity of MMP2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein] Calcium Chloride inhibits the reaction [2,3-dihydroxybenzoic acid results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein] |
CTD |
PMID:10086886 PMID:16159824 PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 More...
|
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity multiple interactions |
ISO EXP |
Calcium Chloride results in increased expression of MMP9 mRNA; Calcium Chloride results in increased expression of MMP9 protein Calcium Chloride results in increased activity of MMP9 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein] |
CTD |
PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC protein] |
CTD |
PMID:12189186 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of NCF1 mRNA; Calcium Chloride results in increased expression of NCF1 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 protein] |
CTD |
PMID:24337353 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [NOS1 protein results in increased reduction of Trinitrotoluene] |
CTD |
PMID:15223068 |
|
NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of NOS2 mRNA Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NOS2 mRNA] |
CTD |
PMID:24337353 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nt5c |
5',3'-nucleotidase, cytosolic |
increases expression |
ISO |
Calcium Chloride results in increased expression of NT5C protein |
CTD |
PMID:25824407 |
|
NCBI chr11:115,381,251...115,382,659
Ensembl chr11:115,381,246...115,382,688
|
|
G |
Nxn |
nucleoredoxin |
increases expression |
ISO |
Calcium Chloride results in increased expression of NXN protein |
CTD |
PMID:25824407 |
|
NCBI chr11:76,148,052...76,289,967
Ensembl chr11:76,148,024...76,289,966
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [PON1 protein results in increased hydrolysis of Paraoxon] |
CTD |
PMID:16052486 |
|
NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946
|
|
G |
Postn |
periostin, osteoblast specific factor |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of POSTN protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458
|
|
G |
Ppid |
peptidylprolyl isomerase D (cyclophilin D) |
increases expression |
ISO |
Calcium Chloride results in increased expression of PPID mRNA; Calcium Chloride results in increased expression of PPID protein |
CTD |
PMID:18614807 |
|
NCBI chr 3:79,498,644...79,511,117
Ensembl chr 3:79,498,649...79,510,957
|
|
G |
Psen2 |
presenilin 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of PSEN2 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:180,054,569...180,091,030
Ensembl chr 1:180,054,569...180,091,003
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of RAD50 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:53,540,346...53,598,146
Ensembl chr11:53,540,346...53,598,146
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression |
ISO |
Calcium Chloride results in increased expression of RECK protein |
CTD |
PMID:25824407 |
|
NCBI chr 4:43,875,521...43,944,806
Ensembl chr 4:43,875,530...43,944,806
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
multiple interactions |
ISO |
[Calcium Chloride co-treated with cuprous chloride] binds to and affects the folding of S100A13 protein; Calcium Chloride binds to and affects the folding of S100A13 protein |
CTD |
PMID:16766622 |
|
NCBI chr 3:90,421,542...90,431,888
Ensembl chr 3:90,421,659...90,431,890
|
|
G |
S100a8 |
S100 calcium binding protein A8 (calgranulin A) |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A8 mRNA; Calcium Chloride results in increased expression of S100A8 protein |
CTD |
PMID:17214633 |
|
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
|
|
G |
S100a9 |
S100 calcium binding protein A9 (calgranulin B) |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A9 mRNA; Calcium Chloride results in increased expression of S100A9 protein |
CTD |
PMID:17214633 |
|
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
|
|
G |
Shc1 |
src homology 2 domain-containing transforming protein C1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of SHC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:89,325,858...89,337,336
Ensembl chr 3:89,325,750...89,337,334
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases activity multiple interactions |
EXP |
Calcium Chloride results in increased activity of SOD2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of SOD2 protein] |
CTD |
PMID:24337353 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of STAT6 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:127,478,855...127,496,856
Ensembl chr10:127,478,855...127,496,826
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
ISO |
[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein] |
CTD |
PMID:33621091 |
|
NCBI chr X:20,726,750...20,787,157
Ensembl chr X:20,726,750...20,787,243
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of TGFB1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
decreases expression multiple interactions |
EXP |
Calcium Chloride results in decreased expression of TIMP1 mRNA Quercetin inhibits the reaction [Calcium Chloride results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:22728078 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of TNF mRNA] cordycepin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein] Calcium Chloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] Calcium Chloride results in increased expression of TNF mRNA; Calcium Chloride results in increased expression of TNF protein |
CTD |
PMID:21530968 PMID:22728078 PMID:36416909 PMID:36731150 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip6 |
tumor necrosis factor alpha induced protein 6 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein]; Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
EXP ISO |
Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; resiniferatoxin promotes the reaction [Calcium Chloride results in increased activity of TRPV1 protein] |
CTD |
PMID:19553475 |
|
NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068
|
|
G |
Ube3b |
ubiquitin protein ligase E3B |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr 5:114,518,578...114,559,226
Ensembl chr 5:114,518,668...114,559,230
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
decreases phosphorylation multiple interactions |
ISO |
Calcium Chloride results in decreased phosphorylation of UQCRFS1 protein [oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; [tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; Cyclosporine inhibits the reaction [[oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein]; Cyclosporine inhibits the reaction [[tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein] |
CTD |
PMID:16023995 |
|
NCBI chr13:30,724,295...30,729,299
Ensembl chr13:30,724,291...30,729,345
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
EXP |
Calcium Chloride results in increased expression of VEGFA mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of BAX protein SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein] |
CTD |
PMID:34333021 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein] |
CTD |
PMID:34333021 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
ISO |
Calcium Oxalate results in decreased expression of CAT protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CAT protein] |
CTD |
PMID:37454925 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Calcium Oxalate results in decreased expression of CCL2 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CCL2 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cd44 |
CD44 antigen |
decreases expression multiple interactions |
ISO |
Calcium Oxalate results in decreased expression of CD44 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CD44 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of NOX2 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
ISO |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
ISO |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions |
ISO |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr X:101,328,244...101,549,005
Ensembl chr X:101,328,245...101,548,965
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of HMOX1 protein phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in increased expression of HMOX1 protein] |
CTD |
PMID:34333021 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor 1 |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of ITPR1 protein Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
|
|
G |
Itpr2 |
inositol 1,4,5-triphosphate receptor 2 |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of ITPR2 protein Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 6:146,009,797...146,403,757
Ensembl chr 6:146,009,797...146,403,721
|
|
G |
Itpr3 |
inositol 1,4,5-triphosphate receptor 3 |
increases expression |
ISO |
Calcium Oxalate results in increased expression of ITPR3 protein |
CTD |
PMID:37454925 |
|
NCBI chr17:27,275,976...27,341,197
Ensembl chr17:27,276,278...27,341,197
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
ISO |
Calcium Oxalate results in increased expression of NOX4 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX4 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in decreased expression of SIRT1 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
decreases expression multiple interactions |
ISO |
Calcium Oxalate results in decreased expression of SOD1 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SOD1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions decreases expression |
ISO |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SPP1 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL10 protein |
CTD |
PMID:14600836 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL12 protein |
CTD |
PMID:14600836 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] [Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:15901796 PMID:19853032 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions affects secretion increases expression |
ISO |
ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the secretion of Rosuvastatin Calcium [Benzbromarone results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Probenecid results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Sulfasalazine results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Rosuvastatin Calcium promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] Rosuvastatin Calcium results in increased expression of ABCC2 protein |
CTD |
PMID:19853032 PMID:23562342 PMID:24909372 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression |
ISO |
Rosuvastatin Calcium results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCG1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions increases activity |
ISO |
[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium Rosuvastatin Calcium results in increased activity of ABCG2 protein |
CTD |
PMID:19853032 PMID:30083819 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
[Piracetam co-treated with Rosuvastatin Calcium] inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]; Rosuvastatin Calcium inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein] |
CTD |
PMID:28441890 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
affects phosphorylation |
ISO |
Rosuvastatin Calcium affects the phosphorylation of AKT1 protein |
CTD |
PMID:27815113 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions increases expression |
ISO |
Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein] |
CTD |
PMID:12767421 PMID:15539964 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of APOB protein |
CTD |
PMID:15539964 PMID:18702965 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of BAX mRNA] |
CTD |
PMID:32007421 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of BCL2 protein |
CTD |
PMID:20852871 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
C3 |
complement component 3 |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of C3 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO EXP |
Rosuvastatin Calcium results in increased activity of CASP3 protein Rosuvastatin Calcium results in increased expression of CASP3 protein |
CTD |
PMID:21478229 PMID:32771489 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
ISO |
Rosuvastatin Calcium results in increased activity of CAT protein [Rosuvastatin Calcium co-treated with Isoproterenol] inhibits the reaction [Interleukin-6 results in increased expression of CAT protein]; Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased activity of CAT protein] |
CTD |
PMID:20146376 PMID:32007421 PMID:35130744 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of CCL2 mRNA |
CTD |
PMID:15681303 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of CREB5 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 6:53,264,154...53,677,349
Ensembl chr 6:53,264,255...53,677,361
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3] |
CTD |
PMID:21562509 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
multiple interactions decreases expression |
ISO |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions decreases expression |
EXP ISO |
Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA] [[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:16633368 PMID:21562509 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of ESR1 protein |
CTD |
PMID:32771489 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of GCLC mRNA [Tetradecanoylphorbol Acetate co-treated with Rosuvastatin Calcium] results in increased expression of GCLC mRNA |
CTD |
PMID:18154958 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of GPR183 mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr14:122,189,743...122,202,605
Ensembl chr14:122,189,963...122,202,607
|
|
G |
Gzmk |
granzyme K |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GZMK mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr13:113,308,164...113,317,499
Ensembl chr13:113,308,142...113,362,442
|
|
G |
Hnf4a |
hepatic nuclear factor 4, alpha |
increases secretion |
EXP |
HNF4A protein results in increased secretion of Rosuvastatin Calcium |
CTD |
PMID:27160211 |
|
NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 1:40,554,548...40,590,867
Ensembl chr 1:40,554,522...40,590,865
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of IL1B mRNA |
CTD |
PMID:15681303 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Rosuvastatin Calcium results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of KCNJ15 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr16:95,058,417...95,101,119
Ensembl chr16:95,058,417...95,101,119
|
|
G |
Kdr |
kinase insert domain protein receptor |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of KDR protein] |
CTD |
PMID:27097221 |
|
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Mb |
myoglobin |
affects expression |
ISO |
Rosuvastatin Calcium affects the expression of MB protein |
CTD |
PMID:27815113 |
|
NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870
|
|
G |
Mstn |
myostatin |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 1:53,100,799...53,107,238
Ensembl chr 1:53,100,799...53,107,238
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of NOS2 mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of NOS2 mRNA] |
CTD |
PMID:21443142 PMID:32007421 PMID:35130744 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions increases expression affects response to substance |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]; Rosuvastatin Calcium results in increased phosphorylation of and results in increased activity of NOS3 protein Rosuvastatin Calcium results in increased expression of NOS3 mRNA NOS3 protein affects the susceptibility to Rosuvastatin Calcium |
CTD |
PMID:12354446 PMID:15681303 PMID:18162361 PMID:21562509 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions decreases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ORM1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400
|
|
G |
Pecam1 |
platelet/endothelial cell adhesion molecule 1 |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PECAM1 protein] |
CTD |
PMID:27097221 |
|
NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454
|
|
G |
Selp |
selectin, platelet |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of SELP mRNA |
CTD |
PMID:15681303 |
|
NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595
|
|
G |
Serpine2 |
serine (or cysteine) peptidase inhibitor, clade E, member 2 |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SERPINE2 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] |
CTD |
PMID:27097221 |
|
NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases expression affects transport |
ISO EXP |
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] Rosuvastatin Calcium results in decreased expression of SLCO1A4 protein SLCO1A4 protein affects the transport of Rosuvastatin Calcium |
CTD |
PMID:19833843 PMID:24909372 PMID:26888941 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1a5 |
solute carrier organic anion transporter family, member 1a5 |
multiple interactions increases uptake |
ISO |
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:28867436 |
|
NCBI chr 6:142,179,953...142,268,707
Ensembl chr 6:142,179,953...142,268,707
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions increases uptake |
ISO |
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:26888941 PMID:31299240 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions increases uptake |
ISO |
Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:24285294 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions increases expression |
ISO |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of TFF1 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
EXP ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] Rosuvastatin Calcium results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15681303 PMID:27097221 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of TNF mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNF protein] |
CTD |
PMID:15681303 PMID:32007421 PMID:35130744 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNNI3 protein] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
G |
Vnn3 |
vanin 3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of VNN3P mRNA |
CTD |
PMID:18192897 |
|
NCBI chr10:23,727,360...23,745,741
Ensembl chr10:23,727,360...23,745,741
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
ISO |
Rosuvastatin Calcium results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961
|
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression |
EXP |
tricalcium phosphate results in increased expression of DNM1L protein |
CTD |
PMID:37678662 |
|
NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
EXP |
tricalcium phosphate results in decreased expression of HMOX1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
affects localization multiple interactions |
EXP |
tricalcium phosphate affects the localization of MAP1LC3B protein Acetylcysteine inhibits the reaction [tricalcium phosphate affects the localization of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein] |
CTD |
PMID:37678662 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Mfn2 |
mitofusin 2 |
decreases expression |
EXP |
tricalcium phosphate results in decreased expression of MFN2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mlkl |
mixed lineage kinase domain-like |
increases phosphorylation multiple interactions |
EXP |
tricalcium phosphate results in increased phosphorylation of MLKL protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein] |
CTD |
PMID:37678662 |
|
NCBI chr 8:112,037,879...112,065,081
Ensembl chr 8:112,038,429...112,064,809
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
decreases expression |
EXP |
tricalcium phosphate results in decreased expression of NFE2L2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
decreases expression |
EXP |
tricalcium phosphate results in decreased expression of NQO1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased expression of PINK1 protein]; tricalcium phosphate results in increased expression of and results in increased localization of PINK1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
increases phosphorylation multiple interactions |
EXP |
tricalcium phosphate results in increased phosphorylation of RIPK1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases phosphorylation multiple interactions |
EXP |
tricalcium phosphate results in increased phosphorylation of RIPK3 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein] |
CTD |
PMID:37678662 |
|
NCBI chr14:56,022,452...56,026,314
Ensembl chr14:56,022,452...56,026,322
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
EXP |
tricalcium phosphate results in decreased expression of SQSTM1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP |
tricalcium phosphate results in decreased expression of TXN1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
EXP |
tricalcium phosphate results in increased expression of TXNIP protein |
CTD |
PMID:37678662 |
|
NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199
|
|